172 related articles for article (PubMed ID: 8044831)
41. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells.
Gorelik L; Bar-Dagan Y; Mokyr MB
J Immunol; 1996 Jun; 156(11):4298-308. PubMed ID: 8666801
[TBL] [Abstract][Full Text] [Related]
42. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
43. Tumoricidal and immunomodulatory activities of drugs and implications for therapy of mice bearing a late stage MOPC-315 plasmacytoma.
Berko R; Seissman K; Colvin M; Bocian RC; Ben-Efraim S; Dray S
Int J Immunopharmacol; 1988; 10(7):825-34. PubMed ID: 3235239
[TBL] [Abstract][Full Text] [Related]
44. Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy.
Shoval S; Ophir R; Ben-Efraim S
Cancer Immunol Immunother; 1989; 29(4):279-87. PubMed ID: 2787695
[TBL] [Abstract][Full Text] [Related]
45. Effect of melphalan administration on the activity of natural killer and natural cytotoxic spleen cells of normal and tumor-bearing mice.
Nahas F; Ophir R; Ben-Efraim S
Immunol Lett; 1985; 10(6):333-7. PubMed ID: 4044020
[TBL] [Abstract][Full Text] [Related]
46. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor.
Mokyr MB; Place AT; Artwohl JE; Valli VE
Cancer Immunol Immunother; 2006 Apr; 55(4):459-68. PubMed ID: 15965646
[TBL] [Abstract][Full Text] [Related]
47. Immunoregulation of murine plasmacytoma. I. Generation of anomalous killer cells in vitro by cocultivation with MOPC 104E.
Hayashida I; Hiramoto RN; Shrestha K; Ghanta VK
Cancer Invest; 1989; 7(1):17-26. PubMed ID: 2567619
[TBL] [Abstract][Full Text] [Related]
48. Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
Mokyr MB; Colvin M; Dray S
Int J Immunopharmacol; 1985; 7(1):111-22. PubMed ID: 3922904
[TBL] [Abstract][Full Text] [Related]
49. Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB; Pyle JM; Dray S
Cancer Immunol Immunother; 1984; 16(3):162-9. PubMed ID: 6561068
[TBL] [Abstract][Full Text] [Related]
50. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
51. Importance of the concomitant presence of palpable MOPC-315 tumor in stimulation of splenocytes by C-type MOPC-315 virus in vitro.
Schwarzbard Z; Ophir R; Gotlieb-Stematsky T; Benefraim S
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1069-75. PubMed ID: 2998801
[TBL] [Abstract][Full Text] [Related]
52. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
Braun DP; Mokyr MB; Dray S
Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
[TBL] [Abstract][Full Text] [Related]
53. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
Wang KC; Berczi I; Sehon AH
Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
[TBL] [Abstract][Full Text] [Related]
54. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
Nio Y; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
[TBL] [Abstract][Full Text] [Related]
55. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
56. Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.
Laude M; Siessmann KL; Mokyr MB; Dray S
Cancer Res; 1991 Sep; 51(17):4516-22. PubMed ID: 1873795
[TBL] [Abstract][Full Text] [Related]
57. Classification of anticancer chemotherapeutic drugs according to their immunopotentiating activity.
Ben-Efraim S; Shoval S; Gal T; Ophir R
Anticancer Res; 1986; 6(4):801-5. PubMed ID: 2944475
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of interleukin-10 (IL-10) production from MOPC 315 tumor cells by IL-10 antisense oligodeoxynucleotides enhances cell-mediated immune responses.
Kim BG; Joo HG; Chung IS; Chung HY; Woo HJ; Yun YS
Cancer Immunol Immunother; 2000 Oct; 49(8):433-40. PubMed ID: 11043850
[TBL] [Abstract][Full Text] [Related]
59. A synthetic thymic hormone, THF-gamma 2, repairs immunodeficiency of mice cured of plasmacytoma by melphalan.
Ophir R; Pecht M; Rashid G; Halperin D; Lourie S; Burstein Y; Ben-Efraim S; Trainin N
Int J Cancer; 1990 Jun; 45(6):1190-4. PubMed ID: 2141006
[TBL] [Abstract][Full Text] [Related]
60. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
